One-time treatment with lasting effects as Sedivention advances obesity therapy with €2.9M funding

Sedivention , a Germany-based medtech startup, has raised €2.9 million in a seed funding round led by bmp Ventures alongside the IBG funds . Additional investors include the strategic investment arm of a global medtech company, High-Tech Gründerfonds (HTGF), superangels, and Cambridge Ventures. The company is developing a minimally invasive, one-time outpatient therapy for the treatment of obesity, a condition expected to affect more than one billion people globally in the coming years.